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Objectives
The aim of the study was to systematically review current studies reporting on clinical outcomes in
people living with HIV (PLHIV) infected with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2).
Methods
We conducted a systematic review using the Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) guidelines. A comprehensive literature search was conducted in Global
Health, SCOPUS, Medline and EMBASE using pertinent key words and Medical Subject Headings
(MeSH) terms relating to coronavirus disease 2019 (COVID-19) and HIV. A narrative synthesis was
undertaken. Articles are summarized in relevant sections.
Results
Two hundred and eighty-five articles were identified after duplicates had been removed. After
screening, eight studies were analysed, totalling 70 HIV-infected patients (57 without AIDS and 13
with AIDS). Three themes were identified: (1) controlled HIV infection does not appear to result in
poorer COVID-19 outcomes, (2) more data are needed to determine COVID-19 outcomes in patients
with AIDS and (3) HIV-infected patients presenting with COVID-19 symptoms should be
investigated for superinfections.
Conclusions
Our findings suggest that PLHIV with well-controlled disease are not at risk of poorer COVID-19
disease outcomes than the general population. It is not clear whether those with poorly controlled
HIV disease and AIDS have poorer outcomes. Superimposed bacterial pneumonia may be a risk
factor for more severe COVID-19 but further research is urgently needed to elucidate whether
PLHIV are more at risk than the general population.
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Introduction
In December 2019, a novel coronavirus, severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2), emerged
in the city of Wuhan, China. SARS-CoV-2 causes coron-
avirus disease 2019 (COVID-19), which has resulted in
the most catastrophic pandemic in modern history [1].
Presentation can be asymptomatic or consist of mild
symptoms, from cough and fever to severe and life-
threatening acute respiratory distress syndrome (ARDS),
sepsis, multi-organ failure and death [2]. There is no cur-
rent specific treatment for COVID-19 but rather organ
support is provided, and severe cases require admission
to hospital for supportive management including
mechanical ventilation.
Evidence is emerging that suggests that increasing age,
hypertension and diabetes are risk factors that correlate
with worse outcomes [3,4]. However, it is not clear if
people living with HIV (PLHIV) are at greater risk than
the general population [5]. Left untreated, HIV infection
results in a reduced number of CD4 T cells, leading to
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AIDS. AIDS is defined as a CD4 T-cell count < 200 cells/
lL [3] or the presence of an AIDS-defining illness [6]. In
2018, it was estimated 37.9 million people worldwide
have HIV infection, 23.3 million of whom are on treat-
ment with antiretroviral therapy (ART) [7]. Eighty-six per
cent of those on treatment have successful viral suppres-
sion, resulting in undetectable viral load and untransmis-
sible disease, known as U = U [8–10]. If ART is
maintained and adhered to, PLHIV are not immunocom-
promised. [11]. Despite this, PLHIV may be at risk of sev-
ere COVID-19, especially in areas where HIV infection is
poorly controlled.
Limited evidence is available on the impact of HIV on
SARS-CoV-2 infection and on whether it has any effect on
COVID-19 outcomes [12]. There is a need to understand
whether PLHIV are at greater risk of severe illness so that
adequate preventative measures can be put in place.
The aim of this systematic review was to identify
studies that discuss PLHIV who have been infected
with SARS-CoV-2 and that report whether coinfection
results in a greater risk of adverse outcomes and,
furthermore, whether controlled HIV infection vs. uncon-
trolled HIV infection or AIDS results in different COVID-
19 disease outcomes. We define controlled HIV infection




A comprehensive literature search was carried out in
Global Health, SCOPUS, Medline and EMBASE to iden-
tify articles that discussed HIV-positive patients and the
clinical implications of HIV infection in COVID-19 in
accordance with the Preferred Reporting Items for Sys-
tematic Reviews and Meta-analysis (PRISMA) guidelines
[13]. Keywords were deconstructed into two categories
(Table 1). Pertinent keywords and Medical Suject Head-
ings (MeSH) terms related to these categories were used
to maximize the output from the literature search. All
relevant articles were identified and screened by two
authors; the results are summarized in a narrative man-
ner in each relevant section within the text of this
review.
Inclusion and exclusion criteria
Inclusion and exclusion criteria are outlined in Table 2.
Studies were included if they discussed the correlation
between confirmed HIV infection and the diagnosis or
prediction of severity of COVID-19.
Data extraction
All articles were screened by two authors and any dis-
agreement was resolved by consensus or the involvement
of a third author. Data were extracted by two authors
and validated by a third author.
Quality assessment
The quality of each publication was evaluated by two
independent reviewers according to a predefined scoring
system, using the National Heart Lung and Blood Institute
(NIH) quality assessment tool for case series and case–
control studies, as appropriate (Table 3) [14].
Statistical analysis
It was not possible to conduct an appropriate meta-anal-
ysis because there were not enough research data in the
studies on this subject.
Results
A PRISMA flow chart for the literature search is shown
in Figure 1. A total of 445 articles were found. After
removal of duplicates, a total of 285 articles were used
for full-text screening and, finally, only eight studies
were included in our analysis. Table 3 summarizes the
study characteristics and the data extracted. A narrative
Table 1 Search terms divided into two categories, coronavirus dis-
ease 2019 (COVID-19) and HIV
Category Search terms
COVID-19 “coronavirus” OR “nCoV*” OR “2019-nCoV” OR “COVID*”
OR “SARS-CoV*”
HIV “HIV” OR “human immunodeficiency virus*” OR “AIDS”
OR “acquired immunodeficiency syndrome”
Table 2 Inclusion and exclusion criteria for the search
Inclusion criteria Exclusion criteria
Exposure: confirmed
diagnosis of COVID-19
Editorials, letters to the editor, consensus
documents, commentaries, and studies
discussing the psychosocial impacts




Published before January 2019
Date range: papers published
from 2019 to present
Does not contain primary data
In the English language In languages other than English
COVID-19, coronavirus disease 2019.
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Table 3 Summary of data extracted from studies included in review
First author
and pub. year Article title Location
Study design
(quality score) Population Population and outcomes
Blanco et al., 2020 COVID-19 in patients
with HIV: clinical case
series
Spain, Barcelona Case series (12/18) • 5 patients with HIV and
SARS-CoV2 infection
○ 4 with undetectable
HIV viral loads and
normal CD4 counts
• 1 patient with AIDS and
ART naive
• Ages < 50
• 4 Male, 2 Transgender
• Symptoms of COVID-19 were the
same as the general population
(cough, fever, malaise and dyspnoea)
• All patients were given ART regimens
with boosted protease inhibitors
• 4 patients given Hydroxychloroquine,
3 Azithromycin, 2 given steroids
Outcomes
• 2 Admissions to ICU
• 4 cured, 1 remained in ICU at the
end of the study
○ The patient with low CD4 was
cured but also had a Pneumocystis
jirovecii infection which was suc-
cessfully treatedwith antibiotics
H€arter et al., 2020 COVID-19 in people
living with human
immunodeficiency





• 32 HIV patients co-in-
fected with SARS-CoV2
○ 4 patients with AIDS
• Mean age 48 (26–82)
Main symptoms did not differ from
general population
Outcomes
• 90% made a full recovery at final
follow up (n = 29)
• 9% mortality (n = 3)
○ 1 patient was 82 with a high HIV
viral load, 1 patient had a low
CD4 count, 1 patient had comor-
bidities including hypertension,
type 2 diabetes and COPD.
• 76% mild cases
• Death, hospitalisation and critical
infection rate were higher than
the general population
• 4 patients with AIDS (low CD4 T-
Cell counts) tested positive for
SARS-CoV-2 and were symp-
tomatic. 1 died, 3 recovered.





China, Wuhan Case series (8/18) • 1178 HIV/AIDS Patients
○ 9 HIV and SARS-CoV2
coinfected patients
○ 1 of these patients
had AIDS
○ Median age 57
○ 8 Male 1 female
• Of 1178 PLHIV contacted, 12 had
symptoms of COVID-19 and 8
tested positive for SARS-CoV2; 6
via nasopharyngeal swab and 2 via
Chest CT Scan (0.68%)
○ All were on ART prior to this
study and had undetectable
HIV viral loads
○ All had normal CD4 counts
○ Slightly higher infection rate
that in Wuhan (0.5%)
○ 6 mild cases, 1 critical case
and 1 death
• Of those who were asymptomatic, 9
had close contact with a known case of
COVID-19. 1 PLHIV tested positive for
SARS-CoV2 via nasopharyngeal swab.
○ This patient had AIDS defining
Kapsosi’s Sarcoma and CD4
count of 27
• Median was higher than the median
age of Wuhan; however this was con-
sistent with the epidemic inWuhan.
© 2020 The Authors.
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Table 3 (Continued)
First author
and pub. year Article title Location
Study design
(quality score) Population Population and outcomes




HIV with a low CD4 T
cell count
China, Wuhan Case report (7/18) • 1 HIV (AIDS) and SARS-
CoV2 coinfected patient




• Patient presented with symptoms
of COVID-19.
• Long disease course of 2 months,
not consistent with COVID-19
• CT Chest confirmed changes con-
sistent with viral pneumonia
• RT-PCR tests from Nasopharyngeal
swabs for SARS-CoV2 tested nega-
tive on 4 occasions
○ One test was positive for
ORF1ab gene but not n-gene
• Patient tested negative for IgM and
IgG to SARS-CoV2on twooccasions
• Patient later tested positive for
SARS-CoV2 IgM, which was a
delayed response
• No other tests for other causes of
viral pneumonia were mentioned
• Received 15% oxygen and then
Methylprednisolone and Moxi-
floxacin after developing a fever
• Patient recovered without ICU or
ventilation
Zhao et al., 2020 Early virus clearance and
delayed antibody
response in a case of
COVID-19 with a
history of co-infection
with HIV-1 and HCV
China, Shenzhen Case report (12/18) • 1 HIV and SARS-CoV2
coinfected patient
○ CD4 count > 200
○ Undetectable HIV viral
load
○ 38 Male
• CT Chest and clinical assessment
confirmed viral pneumonia
• 3 negative SARS-CoV2 tests
• RNAs for Flu A and respiratory
viruses also negative
• Later tested positive for SARS-
CoV2 Antibody IgM and IgG
• IgM titre was low after 42 days,
significantly different to Non-HIV
patients at this point
• Patient made a full recovery without
admission to ICUorneedforventilation




China, Wuhan Case report (10/18) • 1 HIV (AIDS) and SARS-
CoV2 coinfected patient
○ AIDS defining Kaposi’s
Sarcoma
○ CD4 count of 21 (low)
○ Taking ART prior to
COVID-19
• 29 Male
• Patient was also Guo
et al., 2020
• Asymptomatic
• Blood tests showed lymphopenia
• No abnormal findings on chest CT
• Test positive forCOVIDNasopharyngeal
swab and contact tracing was +ve in
January. Not retested on that date.
• Tested in February twice and both
swabs negative.
• He recovered without treatment
but was quarantined in hospital
Haddad et al., 2020 Encephalopathy and
seizure activity in a
COVID-19 well
controlled HIV patient
USA Case report (14/18) • 1 HIV patient with SARS-
CoV-2






• Patient experienced typical symptoms
of COVID-19 at home and was then
hospitalised on day 7 of his illness with
confusion and agitation
• Lumbar puncture was negative
• He started cefepime, ampicillin,
vancomycin, and acyclovir for
empiric bacterial meningitis and
herpes encephalitis coverage which
was discontinued.
• There was marked leukopenia
induced by COVID-19
• He then had a seizure on day 8
and required intubation for 4 days.
• The patient made a full recovery
© 2020 The Authors.
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synthesis was conducted as a consequence of the qualitative
nature of the studies analysed. The themes that emerged
were (1) controlled HIV infection does not appear to result
in poorer COVID-19 outcomes than those found in the gen-
eral population, (2) more data are needed for COVID-19 out-
comes in AIDS patients and (3) HIV-infected patients
presenting with COVID-19 symptoms should be investi-
gated for superinfections. These themes are explored in a
narrative manner in the sections below.
Discussion
Controlled HIV infection (undetectable viral load and
normal CD4 T-cell count) and COVID-19 outcomes
Of the studies analysed, one case report reported a differ-
ence between the symptoms of COVID-19 in PLHIV and
the symptoms of COVID-19 as defined by the WHO [15].
Haddad et al., reported encephalopathy and seizure activ-
ity in a patient with controlled HIV on day 8 of their
symptoms with COVID-19. This was not seen in any other
studies, and the patient made a full recovery [16]. The
other studies included in our review all reported that
symptoms of COVID-19, such as cough, fever, malaise
and breathlessness, in PLHIV were not dissimilar to the
normal population [15]. This indicates that co-infection
HIV and SAR-CoV-2 does not appear to cause a different
presentation. Two studies reported that one patient in
Wuhan was asymptomatic despite a positive RT-PCR test
for SAR-CoV-2 RNA from a nasopharyngeal swab
[17,18]. No other study tested asymptomatic PLHIV and
therefore it is not clear what proportion of PLHIV experi-
ence asymptomatic infection and how this compares to
the general population. The rate of asymptomatic infec-
tion in PLHIV is likely to be underestimated.
Blanco et al. [19], studied five patients in Barcelona;
they report four patients with controlled HIV, three recov-
ered from COVID-19, one patient did not need treatment
and recovered well, whilst another patient had developed
severe COVID-19 and required mechanical ventilation in
ICU. This patient was 49 with hypothyroidism. All patients
were on ART before they were admitted.
H€arter et al. [20], investigated the outcomes of 32
patients coinfected with HIV and SARS-CoV-2 in a retro-
spective case series in Germany. Ninety percent of the
cohort made a full recovery with 76% experiencing mild
symptoms, while the reported mortality was 9%. Mortal-
ity, hospitalisation and critical case rate was higher than
Table 3 (Continued)
First author
and pub. year Article title Location
Study design
(quality score) Population Population and outcomes




USA, New York Case control (22/24) • 21 HIV and SARS-CoV2
coinfected patients
○ 6 patients CD4 T-Cell
count < 200
• Matched to 42 HIV nega-
tive and SARS-CoV2 posi-
tive patients
• HIV positive patients had a Higher
absolute white cell count and CRP
level on admission
○ This did lead to worse out-
comes in these patients
• No statistically significant different
in outcomes but a trend toward an
increased need for ICU admission
and ventilation as well as longer
stays in hospital compared to
matched HIV negative patients
○ This was within the expected
normal reported from other
sites
• No statistical difference in need
for oxygen therapy between the
two cohorts
• 4 patients had superimposed bac-
terial pneumonia (3 HIV positive
and 1 HIV negative)
○ All 4 patients died.
• Did not find a statistical difference
in mortality rate and last reported
CD4 T-Cell count
ART, antiretroviral therapy; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; CT, computed
tomography; ICU, intensive care unit; Ig, immunoglobulin; PLHIV, people living with HIV; RT-PCR, reverse transcriptase–polymerase chain reaction;
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
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the control population. The study only looked at symp-
tomatic patients, so this is likely an overestimation. Of
the three patients that died, one patient was 82 years old,
another had a CD4 T-Cell count of 69/mm3 and the other
patient had multiple comorbidities including hyperten-
sion, type 2 diabetes and chronic obstructive pulmonary
disease (COPD). The mean age of those included in the
study was 48 years old and 90% (30) of the patients were
male, therefore this is not representative of the older pop-
ulation or females with HIV. Confounding factors were
not accounted for in the methodology.
The findings are supported by a similar study in
Wuhan, China by Guo et al. [17] of 1178 patients with
HIV. Eight patients with symptoms were diagnosed with
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) chart for the literature search.
© 2020 The Authors.
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COVID-19 (six via Nasopharyngeal swab and two via CT
Chest). This represented 0.68% of patients with HIV who
were surveyed, slight but not significantly higher than
the percentage of people diagnosed with COVID-19 in
Wuhan (0.5%). Outcomes for were that six recovered fully
after mild illness, one experienced severe illness but
recovered and one patient died. All patients had HIV con-
trolled with ART. Neither study was controlled or
matched for HIV negative patients, however the mortality
rates do not appear to be different to those in the general
population in Wuhan [21]. Zhao et al. [21], also high-
lighted a case study of a HIV patient with SARS-CoV2
co-infection, diagnosis of viral pneumonia was made on
clinical examination and chest CT findings. Three
nasopharyngeal swabs SARS-CoV-2 were negative.
SARS-CoV-2 infection was confirmed with antibody test-
ing at a later date. The patient made a full recovery with-
out the need for admission to ICU or ventilation.
Furthermore, Karmen-Tuohy et al. [22] showed no sta-
tistical difference in outcomes of COVID-19 between
PLHIV and the general population. Twenty-one patients
with HIV and SARS-CoV-2 co-infection were matched to
42 HIV negative patients with SARS-CoV-2, with no dif-
ference in demographics or comorbidities. Twenty of the
21 patients with HIV had normal CD4 T-Cell counts and
were virally suppressed. These patients are not represen-
tative of AIDS patients.
COVID-19 outcomes in patients with AIDS (CD4 T-Cell
Count < 200 cells/mm3)
Blanco et al. [19], reported one case of SARS-CoV-2 in a
patient who was ART na€ıve and a late diagnosis of HIV.
The patient presented with a CD4 T-Cell count of 13
cells/mm3 and had superimposed Pneumocystis jirovecii
pneumonia (an AIDS defining organism) but no other
comorbidities [23]. The patient was admitted to ICU and
required non-invasive ventilation (NIV), responded well
to treatment with oxygen, antibiotics, corticosteroids and
hydroxychloroquine and was discharged after 12 days.
H€arter et al. [20], reported that one patient out of three
who died had a low CD4 T-Cell count of 69 cells/mm3
with no other stated comorbidities. The study also
included three other patients with low CD4 T-Cell counts
who recovered from COVID-19, but no further informa-
tion regarding treatment, disease was given.
Yang et al. [18], presented a case of a patient with a low
CD4 T-Cell Count (21 cells/mm3) and Kaposi’s Sarcoma; this
patient was also discussed by Guo et al. [17] The patient
tested positive for SARS-CoV-2 and remained asymp-
tomatic until two negative tests, with no abnormal findings
on CT chest. In contrast, Wang et al., reported a patient with
34 CD4 T Cells/mm3 who experienced a 2-month disease
course, far exceeding the typical natural history of COVID-
19 [24]. Viral pneumonia was confirmed via CT chest but
SARS-CoV-2 RT-PCR was negative on four occasions. One
positive test for ORF1ab (but not the N-gene) confirmed
SARS-CoV-2. The patient tested negative twice for SARS-
CoV-2 antibodies, but later tested positive for IgM antibod-
ies, indicating a delayed immune response which may
explain the prolonged disease course.
It is not clear if there is an increased risk of worse out-
comes of COVID-19 for AIDS patients. Outcomes in
included studies have ranged from asymptomatic infec-
tion to death. Until more good quality, case-controlled
studies are produced, conclusions cannot be drawn on
this point.
The risk of superimposed bacterial pneumonia
We found reports of superimposed bacterial pneumonia
with COVID-19. These patients generally had poorer out-
comes irrespective of controlled HIV or AIDS. Blanco
et al. [19], described a case of Pneumocystis jirovecii in a
patient with AIDS and COVID-19 which responded well
to antibiotics, as discussed earlier in this review. They
raised the issue of ensuring that pulmonary opportunistic
infections are considered in the differential diagnoses of
SARS-CoV-2 and HIV co-infection, particularly in AIDS
patients. This was supported by Karmen-Tuohy et al. [22],
who found three patients with HIV and COVID-19 devel-
oped superimposed non-AIDS related bacterial pneumo-
nia, compared to only one HIV negative patient with
COVID-19. All of the patients who developed a superim-
posed bacterial pneumonia died in this study, despite
receiving antibiotic treatment. Whilst this is a small
cohort of patients, it highlights potentially worse out-
comes for patients who have a superimposed bacterial
pneumonia with COVID-19. Patients with HIV show a
higher incidence of bacterial pneumonia, which is inver-
sely proportional to CD4 T-Cell count, when compared to
the general population. Thus, superimposed bacterial




Current guidelines for PLHIV
At present, the COVID-19 guidelines for well-controlled
HIV infection state that it is unlikely that PLHIV are at
any greater risk of contracting COVID-19 or experiencing
© 2020 The Authors.
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more severe disease than the general population [12,13].
Our findings support this conclusion, but the data are
currently very limited. The recommendations in both the
UK and USA are in line with the infection control mea-
sures provided to the general public [30]. Specific recom-
mendations include ensuring at least a 30-day supply of
ART and advising up-to-date vaccinations including
pneumococcal and influenza vaccines [12–14]. Clinicians
should reassure PLHIV that, if the HIV infection is con-
trolled, their risk of serious complications of COVID-19
and therefore poor outcomes is likely to be low. However,
the presence of known COVID-19 risk factors may put
them at greater risk of worse outcomes. The same cannot
be said for poorly controlled HIV infection or AIDS.
SARS, Middle East respiratory syndrome (MERS) and
H1N1
In previous outbreaks of SARS, H1N1 and Middle East
respiratory syndrome (MERS), HIV infection was not
associated with increased disease severity. In the SARS
and MERS outbreaks, there were only a few reports of
mild disease among PLHIV [31,32]. The risk factors for
these outbreaks were similar to those being observed for
SARS-CoV-2. H1N1 outcomes were similar to outcomes
for SARS-CoV-2, whereby clinical outcomes of those with
well-controlled HIV infection were similar to those of the
general population [33,34]. A literature review by Cooper
[35] further highlighted that HIV-infected patients and
patients who were immunocompromised for other reasons
recovered from H1N1 infection without complications.
SARS-CoV-2 cannot be presumed to be the same as these
viruses. We do not know enough about its mechanisms of
action to be sure of the impact of HIV infection in those
coinfected with SARS-CoV-2 and HIV. However, data from
previous outbreaks are reassuring at least in that well-con-
trolled HIV infection did not pose a greater risk of more sev-
ere disease compared with the general population.
PLHIV with undiagnosed HIV infection and those with
a confirmed diagnosis not being treated with ART
We identified a small number of studies specifically look-
ing at PLHIV and COVID-19. We identified two patients
who were diagnosed with HIV infection at the same time
as SARS-CoV-2 infection who were ART na€ıve [19,24] .
Both patients had low CD4 T-cell counts. In 2018, an
estimated 8.1 million cases of HIV infection globally were
undiagnosed and 28% of patients known to be infected
were not on treatment [7]. We recommend that, if a clini-
cal picture suggests viral pneumonia, such as symptoms
of COVID-19 or typical viral pneumonitis on a computed
tomography (CT) scan (including mild and severe cases of
COVID-19), patients should be offered testing for HIV to
rule out undetected HIV infection.
Confirmation of COVID-19, differential diagnosis and
coinfection
We found a disparity in methods of COVID-19 diagnosis
between studies. In six studies, SARS-CoV-2 was con-
firmed by reverse transcriptase–polymerase chain reaction
(RT-PCR) [16-20, 22], and in two studies COVID-19 was
diagnosed using CT thorax findings [17, 21].In order to
ensure that the diagnosis of COVID-19 is correct and
other differential diagnosis are ruled out , we suggest that
future studies reporting detection of the virus should use
a consistent method of diagnosising COVID-19. Also,
other causes of pneumonia should be screened for and
ruled out to ensure that data are accurate both to confirm
the causative agent and to identify any coinfection that
may exacerbate symptoms and severity of COVID-19.
Viral pneumonia is generally more severe if a concurrent
bacterial pneumonia is present, in both the normal population
and PLHIV. This is a plausible reason why some patients
included in this review had more severe COVID-19 [25–29].
We recommend that sputum and blood cultures should be
taken early for detection of superimposed bacterial pneumonia
and the presence of other causative agents.
Wider considerations for PLHIV during the
COVID-19 pandemic
Telemedicine
The continuation of out-patient care for PLHIV presents
unique challenges as hospitals deal with COVID-19 patients.
PLHIV could be deterred from accessing HIV care as a conse-
quence of the perceived risks of attending hospitals, and also
the risk that out-patient services may be affected by the re-de-
ployment of health care professionals to other areas of the
hospital. This presents an opportunity for the advancement of
telemedicine, the remote diagnosis and treatment of a patient
using technology. Young et al. [36] and Ohl et al. [37] both
found that, where telemedicine was available to patients,
greater viral suppression was achieved. Rogers et al. [38] have
described an effective implementation of telemedicine in a
clinic in the USA, to ensure continuity of care during the
COVID-19 pandemic. Clinics who implemented telemedicine
also reported fewer missed appointments and higher patient
engagement. Furthermore, studies showed that text message
services resulted in significant improvements in ART adher-
ence and rates of viral suppression in sub-Saharan Africa
[39,40].
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Telemedicine can therefore be effectively used to man-
age patients with HIV infection, without the need for
them to attend clinic, allowing patients to avoid unneces-
sary journeys to hospitals and clinics and to maintain
social distancing. Having said this. as stressed by Mgbako
et al. [41], this must be led by a patient-centred
approach, ensuring good communication as well as a
good professional–patient relationship.
The psychological impact of COVID-19 on PLHIV
The disruption in the continuity of care for PLHIV,
increased social isolation and the psychological stress of
living through a pandemic are all factors that could wor-
sen the mental health problems that PLHIV are at a
higher risk of experiencing [42]. PLHIV are more likely to
experience social isolation; however, as a consequence of
measures to prevent the spread of COVID-19, this experi-
ence may be amplified, which may have a negative effect
on mental health [43]. Furthermore, COVID-19 will
potentially exacerbate other psychological stressors such
as food insecurity and increased societal stigma
[42,44,45]. These psychosocial stressors further may
increase the risk of adverse health outcomes among
PLHIV as a consequence of reduced medication adher-
ence, leading to failure to achieve adequate HIV manage-
ment [42].
Future research
Whilst further high-quality studies would be beneficial to
confirm that there is no difference in outcomes of
COVID-19 between PLHIV who have controlled HIV
infection and the general population, as a consequence of
the gap in knowledge about outcomes in AIDS patients
with COVID-19, there needs to be an urgent focus on
high-quality research looking at outcomes for patients
with AIDS and COVID-19. Furthermore, more research
into the impact and incidence of superimposed bacterial
pneumonia is needed in both the general population and
PLHIV. This would help to influence management and
provide a good basis for developing treatment pathways
that may reduce the trend towards higher mortality.
Limitations
The limitations of this review were the small number of
studies included in our analysis that were relevant to our
outcomes. The studies included were all case series or
case reports with small sample sizes, and confounding
variables were not accounted for in the reporting of such
data. We acknowledge that, in view of the nature of the
study designs included in our analysis, our interpretations
and conclusions should be treated with caution.
Conclusions
Our findings indicate that currently PLHIV are not likely
to be at increased risk of poorer outcomes of COVID-19
disease than the general population if they have an unde-
tectable viral load and an adequate CD4 count. This sug-
gests that well-managed HIV infection is not a risk factor
for more severe COVID-19. However, it is unknown if
poorly controlled HIV infection and AIDS put people at a
greater risk of severe COVID-19. Bacterial superinfection
appears to be a potential risk factor for poorer outcomes
in PLHIV. Therefore, our findings highlight the need for
further investigation to elucidate the impact of HIV infec-
tion in COVID-19.
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